| 1 |
卢亚楠，李童星，胡焕丽. 重症肺炎患者菌群分布特点及预后不良风险预测模型构建和验证[J]. 中国病原生物学杂志，2025, 20(8): 1035-1040.
|
| 2 |
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258): 1204-1222.
|
| 3 |
Grasselli G, Tonetti T, Protti A, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study[J]. Lancet Respir Med, 2020, 8(12): 1201-1208.
|
| 4 |
Polito MV, Silverio A, Bellino M, et al. Cardiovascular Involvement in COVID-19: What Sequelae Should We Expect？[J]. Cardiol Ther, 2021, 10(2): 377-396.
|
| 5 |
Vohwinkel CU, Burns N, Coit E, et al. HIF1A-dependent induction of alveolar epithelial PFKFB3 dampens acute lung injury[J]. JCI insight, 2022, 7(24): e157855.
|
| 6 |
Pilarczyk K, Huenges K, Bewig B, et al. Acute kidney injury in patients with severe ARDS requiring extracorporeal membrane oxygenation: incidence, prognostic impact and risk factors[J]. J Clin Med, 2022, 11(4): 1079.
|
| 7 |
魏丁，乔艳艳，顾兴，等. 体外膜肺氧合救治急性呼吸窘迫综合征不良预后危险因素分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(3): 363-367.
|
| 8 |
Combes A, Peek GJ, Hajage D, et al. ECMO for severe ARDS: systematic review and individual patient data meta-analysis[J]. Intensive care medicine, 2020, 46(11): 2048-2057.
|
| 9 |
中华医学会重症医学分会. 严重急性呼吸窘迫综合征体外膜肺氧合治疗中国专家共识[J/OL]. 中华重症医学电子杂志(网络版), 2020, 6(3): 201-216.
|
| 10 |
Blum JM, Lynch WR, Coopersmith CM. Clinical and billing review of extracorporeal membrane oxygenation[J]. Chest, 2015, 147(6): 1697-1703.
|
| 11 |
Peek GJ, Mugford M, Tiruvoipati R, et al. CESAR trial collaboration. Efficacy and economic assessment of conventional ventilatory support versus extracorporealmembrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial[J]. Lancet, 2009, 374(9698): 1351-1363.
|
| 12 |
Chan KM, Wan WTP, Ling L, et al. Management of circuit air in extracorporeal membrane oxygenation: a single center experience[J]. ASAIO J, 2022, 68(3): e39-e43.
|
| 13 |
Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study[J]. Lancet Infect Dis, 2020, 20(10): 1135-1140.
|
| 14 |
Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia[J]. J Thromb Haemost, 2020, 18(4): 844-847.
|
| 15 |
Bonaventura A, Vecchié A, Dagna L, et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19[J]. Nat Rev Immunol, 2021, 21(5): 319-329.
|
| 16 |
Nagashima S, Mendes MC, Camargo Martins AP, et al. Endothelial dysfunction and thrombosis in patients with COVID-19-brief report[J]. Arterioscler Thromb Vasc Biol, 2020, 40(10): 2404-2407.
|
| 17 |
Kuzmin B, Wacker M, Ponomarenko J, et al. Anticoagulation management during veno-venous ECMO support because of ARDS: Single-center experience[J]. Heliyon, 2024, 10(22): e40417.
|
| 18 |
徐旺，王赛妮，李华娟，等. 肺泡灌洗液宏基因组二代测序辅助诊断肺隐球菌病一例[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(1): 132-134.
|
| 19 |
陈婷婷，江文洁，华晓兰，等. 宏基因组二代测序在肺部感染患者病原体检测中的应用价值[J]. 广西医科大学学报，2022, 39(5): 820-825.
|
| 20 |
Zeng W, Liang Y, He X, et al. Exploring the pathogen diagnosis and prognostic factors of severe COVID-19 using metagenomic next-generation sequencing: A retrospective study[J]. J Med Biochem, 2024, 43(4): 528-536.
|
| 21 |
Ong SWX, Tong SYC. Target trial emulation for antibiotic use in acute COVID-19-taking aim at a common intervention[J]. JAMA Netw Open, 2025, 8(5): e2511507.
|
| 22 |
Sah SK, Shariff A, Pathakamuri N, et al. Antifungal therapy in the management of fungal secondary infections in COVID-19 patients: A systematic review and meta-analysis[J]. PLoS One, 2022, 17(7): e0271795.
|